ANAB

AnaptysBio Inc

48.28

Oct 30 • 3:59 PM ET -0.36 (-0.74%)

48.28

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: RPRX INVA LGND HALO TRAX OABI ABCL GSK REGN MRK

| Held by: XBI VTI IWM VXF IBB PBE IWO DFAS FYC VTWO

Scroll to Statements

Index	RUT
Market Cap	1.44B
Enterprise Value	1.55B
Income	195.72M
Sales	237.61M
Book/sh	0.36
Cash/sh	5.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	104
IPO	Jan 26, 2017

P/E	7.49
Forward P/E	-
PEG	-
P/S	6.07
P/B	135.60
P/C	8.79
P/FCF	79.87
EV/EBITDA	11.38
EV/Sales	6.52
Quick Ratio	5.61
Current Ratio	5.61
Debt/Eq	25.46
LT Debt/Eq	25.25
Option/Short	Yes / Yes

EPS (ttm)	6.45
EPS next Y	-
EPS next Q	0.85
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	53.48% 8.82%
Sales past 3/5Y	183.58% 25.62%
EPS Y/Y TTM	249.01%
Sales Y/Y TTM	92.92%
EPS Q/Q	561.29%
Sales Q/Q	23.47%
Earnings	Sep 21 AMC
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	6.62%
Insider Trans	-0.25%
Inst Own	102.98%
Inst Trans	5.15%
ROA	70.78%
ROE	-114.55%
ROIC	70.40%
Gross Margin	96.78%
Oper. Margin	56.36%
Profit Margin	82.37%
SMA20	1.24%
SMA50	-6.72%
SMA200	-4.21%
Trades

Shs Outstand	29.73M
Shs Float	27.92M
Short Float	19.31%
Short Ratio	10.83
Short Interest	5.39M
52W High	72.36 -33.28%
52W Low	20.18 139.28%
Volatility	3.51% 4.58%
ATR (14)	2.25
RSI (14)	46.75
Beta	0.85
Rel Volume	0.59
Avg Volume	497.69K
Volume	293,633

Perf Week	-0.92%
Perf Month	-0.72%
Perf Quarter	-10.03%
Perf Half Y	-27.68%
Perf YTD	49.40%
Perf Year	98.60%
Perf 3Y	339.24%
Perf 5Y	120.15%
Perf 10Y	-
Recom	1.14
Target Price	79.71
Prev Close	48.64
Price	48.28
Change %	-0.74%

Consensus

Strong Buy

Avg. Price Target

$79.71

Implied Upside

+65.1%

Analysts14incl. previous ratings

Rating Distribution12 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 10, 2026	Resumed	HH.C. Wainwright	Buy	$95	+96.8%
Jan 07, 2026	Resumed	UUBS	Buy	$70	+45.0%
Oct 13, 2025	Initiated	BBarclays	Overweight	$78	+61.6%
Jun 04, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$38	-21.3%
Feb 04, 2025	Initiated	WWolfe Research	Outperform	$25	-48.2%
Dec 11, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral	$52 → $19	-60.6%
Dec 02, 2024	Downgrade	BBTIG Research	Buy → Neutral
Jul 22, 2024	Initiated	HH.C. Wainwright	Buy	$55	+13.9%
Jul 19, 2024	Upgrade	JJP Morgan	Neutral → Overweight	$29 → $69	+42.9%
Apr 16, 2024	Initiated	LLeerink Partners	Outperform	$47	-2.7%
Apr 11, 2024	Initiated	WWells Fargo	Overweight	$56	+16.0%
Mar 12, 2024	Upgrade	WWedbush	Neutral → Outperform	$20 → $34	-29.6%
Feb 26, 2024	Initiated	BBTIG Research	Buy	$55	+13.9%
Feb 21, 2024	Initiated	SStifel	Buy	$50	+3.6%
Feb 16, 2024	Initiated	PPiper Sandler	Overweight	$80	+65.7%
May 22, 2023	Upgrade	JJP Morgan	Underweight → Neutral	$31 → $30	-37.9%
May 18, 2023	Initiated	TTD Cowen	Outperform
Jan 06, 2023	Downgrade	RRaymond James	Outperform → Mkt Perform
Nov 01, 2022	Upgrade	GGuggenheim	Neutral → Buy	$44	-8.9%
Sep 19, 2022	Resumed	HH.C. Wainwright	Buy	$35	-27.5%

Oct-19-26 02:18PM	Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer (GlobeNewswire) +5.64%
Sep-21-26 04:15PM	Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update (GlobeNewswire)
Sep-01-26 04:15PM	Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
May-12-26 04:15PM	Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-11-26 09:15AM	Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors (GlobeNewswire)
04:15PM	Loading…
May-04-26 04:15PM	Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-28-26 07:12PM	Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence (PR Newswire) -5.70%
Apr-27-26 02:58AM	GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio (Proactive) +13.09%
Apr-24-26 03:40PM	Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim (GlobeNewswire) +14.84%
Apr-20-26 09:15AM	Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations (GlobeNewswire) +13.22%
Mar-27-26 09:00AM	First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement (GlobeNewswire) -11.68%
09:00AM	Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics (GlobeNewswire)
09:00AM	Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update (GlobeNewswire)
Mar-04-26 12:47PM	AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference (MarketBeat) +14.61%
Mar-03-26 05:35PM	AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates (Zacks)
04:15PM	Loading…
04:15PM	Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-12-26 03:08PM	AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 (MarketBeat)
Feb-11-26 04:05PM	AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts (MarketBeat) +9.97%
Feb-05-26 04:15PM	Anaptys Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-26 01:57PM	Biotech Leader Eyes Spin-Off Amid Massive Sales Surge (Investor's Business Daily)
Jan-13-26 11:02PM	AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf (MarketBeat)
Jan-09-26 01:56PM	AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties (Benzinga)
Jan-08-26 06:00PM	Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary (GlobeNewswire)
Jan-06-26 04:15PM	Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 12:05PM	This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving (Barchart)
Dec-15-25 07:00AM	Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis (PR Newswire)
Nov-25-25 04:15PM	Anaptys Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-21-25 04:47PM	AnaptysBio Reverses Higher After Trading Legal Barbs With Pharma Giant GSK (Investor's Business Daily) +5.18% +5.91%
06:14AM	GSK, AnaptysBio Sue Each Other Over Cancer Drug License (The Wall Street Journal)
04:00AM	Anaptys Announces $100 Million Stock Repurchase Plan (GlobeNewswire)
03:50AM	Loading…
03:50AM	Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary (GlobeNewswire)
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-10-25 11:25AM	Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run (Investor's Business Daily) -14.30%
09:00AM	Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
Nov-04-25 05:50PM	AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-29-25 10:00AM	Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:15AM	Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation (GlobeNewswire)
Oct-28-25 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-13-25 09:15AM	Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 (GlobeNewswire)
Sep-29-25 04:05PM	Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 (GlobeNewswire) +31.59%
04:05PM	Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 (GlobeNewswire)
Aug-27-25 04:15PM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-06-25 05:25PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.63%
04:15PM	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:00AM	AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jun-03-25 04:05PM	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA (GlobeNewswire) +7.59% -9.57%
May-27-25 04:15PM	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 (GlobeNewswire)
May-12-25 03:53PM	AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-05-25 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire) +7.82%
Mar-25-25 09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-24-25 09:15AM	Anaptys Announces Stock Repurchase Plan (GlobeNewswire) +9.54%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-25 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Participation in March Investor Conferences (GlobeNewswire)
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-25 10:00AM	Truist says AnaptysBio handing of placebo raise doubt about Phase 2 RA data (TipRanks) +19.44%
09:40AM	Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? (Zacks)
05:11AM	AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? (Zacks)
Feb-12-25 12:22PM	AnaptysBio achieves highest ever results in Phase II rheumatoid arthritis trial (Clinical Trials Arena) +30.51%
09:23AM	AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment (Investor's Business Daily)
07:30AM	Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months (GlobeNewswire)
Feb-11-25 05:30PM	Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 (GlobeNewswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 04:15PM	Anaptys to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -7.08%
07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-27-25 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks)
Jan-13-25 09:42AM	How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry (Zacks)
Jan-12-25 03:00AM	Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser (Barrons.com)
Jan-07-25 09:15AM	Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 05:23AM	AnaptysBios atopic dermatitis trial of BTLA agonist misses endpoints (Clinical Trials Arena)
Dec-11-24 02:07PM	AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data (Benzinga) -32.83%
08:30AM	Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis (GlobeNewswire)
Nov-25-24 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks) +8.22%
Nov-08-24 12:00PM	AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) (Zacks)
Nov-05-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.72%
04:15PM	Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November and December Investor Conferences (GlobeNewswire)
Aug-29-24 09:15AM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-23-24 07:26AM	Why AnaptysBio Was Such a Healthy Stock This Week (Motley Fool)
Aug-14-24 04:11PM	AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily) -6.35%
10:05AM	AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily)
05:00AM	Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire)
Aug-05-24 09:54PM	ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:55PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-24 02:53PM	AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst (Benzinga) +5.96%
May-09-24 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.75%
04:15PM	Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
04:05PM	Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties (GlobeNewswire)
May-02-24 10:01AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-01-24 04:51AM	AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +6.90%
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace) -6.34%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RENTON HOLLINGS	Director	Oct 01 '26	Option Exercise	18.03	5,000	90,150	15,995	Oct 02 05:47 PM
RENTON HOLLINGS	Director	Oct 01 '26	Sale	49.87	5,000	249,372	10,995	Oct 02 05:47 PM
HOLLINGS C RENTON	Director	Oct 01 '26	Proposed Sale	49.87	5,000	249,372		Oct 01 04:07 PM
Orwin John A	Director	Sep 15 '26	Option Exercise	0.00	1,300	0	17,995	Sep 17 04:05 PM
JOE ANTHONY WARE	Director	Jul 13 '26	Proposed Sale	67.17	10,694	718,333		Jul 13 04:12 PM
JOE ANTHONY WARE	Director	Jun 30 '26	Proposed Sale	67.79	6,030	408,774		Jun 30 04:04 PM
DENNIS MULROY	Officer	Jun 29 '26	Proposed Sale	63.45	9,476	601,213		Jun 29 04:15 PM
DENNIS MULROY	Officer	Jun 26 '26	Proposed Sale	60.82	10,000	608,183		Jun 26 04:46 PM
DENNIS MULROY	Officer	Jun 17 '26	Proposed Sale	60.00	850	51,000		Jun 17 04:29 PM
Schmid John P.	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	37,652	Jun 17 04:05 PM
RENTON HOLLINGS	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	10,995	Jun 17 04:05 PM
Orwin John A	Director	Jun 15 '26	Option Exercise	0.00	6,030	0	16,695	Jun 17 04:05 PM
DENNIS MULROY	Officer	Jun 16 '26	Proposed Sale	60.00	1,265	75,900		Jun 16 05:28 PM
DENNIS MULROY	Officer	Jun 15 '26	Proposed Sale	57.65	20,000	1,153,014		Jun 15 05:47 PM
DENNIS MULROY	Officer	Jun 12 '26	Proposed Sale	55.30	20,000	1,105,940		Jun 12 04:07 PM
DENNIS MULROY	Officer	Jun 11 '26	Proposed Sale	52.82	35,000	1,848,750		Jun 11 04:47 PM
DENNIS MULROY	Officer	Jun 10 '26	Proposed Sale	52.33	20,000	1,046,560		Jun 10 04:38 PM
DENNIS MULROY	Officer	Jun 09 '26	Proposed Sale	51.61	20,000	1,032,230		Jun 09 05:08 PM
DENNIS MULROY	Officer	Jun 08 '26	Proposed Sale	50.83	21,987	1,117,704		Jun 08 05:20 PM
DENNIS MULROY	Officer	Jun 05 '26	Proposed Sale	51.29	22,491	1,153,671		Jun 05 05:22 PM
DENNIS MULROY	Officer	Jun 04 '26	Proposed Sale	51.77	20,000	1,035,438		Jun 05 12:36 PM
DENNIS MULROY	Officer	Jun 03 '26	Proposed Sale	50.86	20,000	1,017,250		Jun 03 05:16 PM
DENNIS MULROY	Officer	Jun 02 '26	Proposed Sale	51.65	20,000	1,033,096		Jun 02 04:37 PM
DENNIS MULROY	Officer	Jun 01 '26	Proposed Sale	52.57	7,691	404,340		Jun 01 05:50 PM
DENNIS MULROY	Officer	May 29 '26	Proposed Sale	55.66	15,000	834,903		May 29 04:11 PM
DENNIS MULROY	Officer	May 28 '26	Proposed Sale	57.94	10,264	594,671		May 28 05:17 PM
DENNIS MULROY	Officer	May 27 '26	Proposed Sale	58.50	10,000	585,006		May 27 04:46 PM
DENNIS MULROY	Officer	May 26 '26	Proposed Sale	57.60	10,000	576,000		May 26 04:17 PM
DENNIS MULROY	Officer	May 22 '26	Proposed Sale	59.30	10,000	593,008		May 22 04:04 PM
DENNIS MULROY	Officer	May 21 '26	Proposed Sale	60.00	15,467	928,071		May 21 04:01 PM
DENNIS MULROY	Officer	May 19 '26	Proposed Sale	59.90	10,000	599,000		May 19 05:37 PM
DENNIS MULROY	Officer	May 15 '26	Proposed Sale	63.25	10,000	632,543		May 15 04:10 PM
Schmid John P.	Director	Mar 30 '26	Sale	56.11	20,645	1,158,451	31,622	Apr 01 09:28 PM
JOHN SCHMID	Director	Mar 30 '26	Proposed Sale	56.11	20,645	1,158,451		Mar 30 05:28 PM
Faga Daniel	President, CEO	Mar 27 '26	Sale	61.61	17,679	1,089,199	495,965	Mar 27 08:15 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Feb 11 '26	Option Exercise	29.70	10,000	297,000	22,835	Feb 13 04:05 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Feb 11 '26	Sale	54.00	10,000	540,000	12,835	Feb 13 04:05 PM
ERIC J LOUMEAU	Officer	Feb 11 '26	Proposed Sale	54.00	10,000	540,000		Feb 11 04:36 PM
Marquet Magda	Director	Jan 15 '26	Option Exercise	26.11	11,000	287,210	20,930	Jan 16 01:05 PM
Marquet Magda	Director	Jan 15 '26	Sale	48.23	11,000	530,531	9,930	Jan 16 01:05 PM
MAGDA MARQUET	Director	Jan 15 '26	Proposed Sale	48.23	11,000	530,531		Jan 15 04:06 PM
Lizzul Paul F.	Chief Medical Officer	Jan 08 '26	Sale	44.71	3,650	163,192	42,088	Jan 09 07:16 PM
Paul F. Lizzul	Officer	Jan 08 '26	Proposed Sale	45.21	3,650	165,016		Jan 09 07:15 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 08 '26	Sale	44.71	2,515	112,446	21,852	Jan 09 07:14 PM
DENNIS MULROY	Officer	Jan 08 '26	Proposed Sale	45.21	2,515	113,703		Jan 09 07:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 08 '26	Sale	44.71	2,210	98,809	12,835	Jan 09 07:13 PM
ERIC J LOUMEAU	Officer	Jan 08 '26	Proposed Sale	45.21	2,210	99,914		Jan 09 07:12 PM
Faga Daniel	President, CEO	Jan 08 '26	Sale	44.71	14,281	638,504	479,344	Jan 09 07:12 PM
Daniel Faga	Officer	Jan 08 '26	Proposed Sale	45.21	14,281	645,644		Jan 09 07:11 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 07 '26	Sale	45.56	9,639	439,200	9,157	Jan 08 04:12 PM
ERIC J LOUMEAU	Officer	Jan 07 '26	Proposed Sale	43.91	2,017	88,566		Jan 08 04:12 PM
Lizzul Paul F.	Chief Medical Officer	Jan 07 '26	Sale	45.11	2,235	100,821	37,213	Jan 08 04:11 PM
Paul F. Lizzul	Officer	Jan 07 '26	Proposed Sale	43.91	2,235	98,139		Jan 08 04:10 PM
Faga Daniel	President, CEO	Jan 07 '26	Sale	45.11	9,202	415,102	466,787	Jan 08 04:10 PM
Daniel Faga	Officer	Jan 07 '26	Proposed Sale	43.91	9,202	404,060		Jan 08 04:09 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 07 '26	Sale	45.11	1,908	86,070	17,667	Jan 08 04:08 PM
DENNIS MULROY	Officer	Jan 07 '26	Proposed Sale	43.91	1,908	83,780		Jan 08 04:08 PM
ERIC J LOUMEAU	Officer	Jan 07 '26	Proposed Sale	45.69	7,622	348,213		Jan 07 04:06 PM
Faga Daniel	President, CEO	Jan 05 '26	Sale	43.26	15,309	662,267	458,139	Jan 06 09:07 PM
Daniel Faga	Officer	Jan 05 '26	Proposed Sale	44.95	15,309	688,140		Jan 06 09:07 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 05 '26	Sale	43.26	3,363	145,483	14,330	Jan 06 09:05 PM
DENNIS MULROY	Officer	Jan 05 '26	Proposed Sale	44.95	3,363	151,167		Jan 06 09:05 PM
Lizzul Paul F.	Chief Medical Officer	Jan 05 '26	Sale	43.26	4,219	182,514	33,303	Jan 06 09:04 PM
Paul F. Lizzul	Officer	Jan 05 '26	Proposed Sale	44.95	4,219	189,644		Jan 06 09:04 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 05 '26	Sale	43.26	2,983	129,045	13,251	Jan 06 09:03 PM
ERIC J LOUMEAU	Officer	Jan 05 '26	Proposed Sale	44.95	2,983	134,086		Jan 06 09:02 PM
Ware J. Anthony	Director	Dec 23 '25	Sale	49.58	3,900	193,342	9,630	Dec 23 04:30 PM
Lizzul Paul F.	Chief Medical Officer	Dec 22 '25	Option Exercise	18.50	1,500	27,750	28,467	Dec 23 04:28 PM
Lizzul Paul F.	Chief Medical Officer	Dec 22 '25	Sale	50.00	1,500	75,000	26,967	Dec 23 04:28 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 22 '25	Option Exercise	20.16	10,000	201,600	19,401	Dec 23 04:28 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 22 '25	Sale	50.00	10,000	500,000	9,401	Dec 23 04:28 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 22 '25	Option Exercise	14.02	10,000	140,200	18,947	Dec 23 04:27 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 22 '25	Sale	51.00	10,000	510,000	8,947	Dec 23 04:27 PM
JOE ANTHONY WARE	Director	Dec 23 '25	Proposed Sale	49.58	3,900	193,342		Dec 23 04:03 PM
ERIC J LOUMEAU	Officer	Dec 22 '25	Proposed Sale	51.00	10,000	510,000		Dec 22 04:05 PM
PAUL F LIZZUL	Officer	Dec 22 '25	Proposed Sale	50.00	1,500	75,000		Dec 22 04:04 PM
DENNIS MULROY	Officer	Dec 22 '25	Proposed Sale	50.00	10,000	500,000		Dec 22 04:01 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 16 '25	Option Exercise	17.70	12,500	221,300	21,588	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 17 '25	Option Exercise	14.02	10,000	140,200	19,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 16 '25	Sale	44.86	12,500	560,800	9,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 17 '25	Sale	46.00	10,000	460,000	9,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 18 '25	Sale	46.99	141	6,626	8,947	Dec 18 04:14 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 16 '25	Option Exercise	20.16	10,000	201,600	25,126	Dec 18 04:13 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 16 '25	Sale	44.85	15,725	705,333	9,401	Dec 18 04:13 PM
ERIC J LOUMEAU	Officer	Dec 18 '25	Proposed Sale	46.99	141	6,626		Dec 18 04:11 PM
ERIC J LOUMEAU	Officer	Dec 17 '25	Proposed Sale	46.00	10,000	460,000		Dec 17 04:12 PM
DENNIS MULROY	Officer	Dec 16 '25	Proposed Sale	44.85	15,725	705,333		Dec 16 04:58 PM
ERIC J LOUMEAU	Officer	Dec 16 '25	Proposed Sale	44.86	12,500	560,800		Dec 16 04:09 PM

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm's product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

PresidentMr. Daniel R. Faga

Chief Financial OfficerMr. Christopher M. Murphy

Senior Vice President of Human ResourcesMs. Beth Mueller

Chief Business OfficerMr. Benjamin Stone

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANAB

AnaptysBio Inc

Upgrade your Finviz experience